OncologyTube Professional - Patients Click Here
23,199 video views
Loading........
Description: Lee S. Schwartzberg, MD of University of Tennessee Health Science Center explains which patients should get endocrine therapy and genomic profiling in breast cancer. This was recorded at the 2017 Nati...
00:57
Lee S. Schwartzberg, MD of University of Tennessee Health Science Center explains which patients should get endocrine therapy and genomic profiling in breast cancer. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™ in Orlando, Florida....
by:NCCN2017 | 699 views
00:36
Lee S. Schwartzberg, MD of University of Tennessee Health Science Center explains the use of genomic profiling for prognoses in breast cancer, which shows the chances of relapse and a prediction for endocrine therapy or chemotherapy. He states that with genomic profiling, oncologists can tailor thei...
by:NCCN2017 | 830 views
00:48
Lee S. Schwartzberg, MD of University of Tennessee Health Science Center discusses the treatment trends in 2017 for estrogen receptor positive breast cancer, which include the use of CDK46 inhibitors. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Impro...
by:NCCN2017 | 519 views
00:53
Lee S. Schwartzberg, MD of University of Tennessee Health Science Center discusses current clinical trials and genomic profiling in breast cancer research. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™ in Orlando, Florida.
by:NCCN2017 | 808 views
01:15
Shaji K. Kumar, MD of Mayo Clinic gives an overview of the upcoming treatment trends for multiple myeloma, which include combination therapy after relapse, longer duration of treatment, early intervention, and clinical trials development. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Qua...
by:NCCN2017 | 947 views
01:09
Shaji K. Kumar, MD of Mayo Clinic discusses how to gain a better understanding in treating multiple myeloma. He states that most patients who are treated end up relapsing, so oncologists need to figure out why they continue to relapse and how does the disease evolve over time. Ultimately, oncologist...
by:NCCN2017 | 810 views
00:43
Matthew H. Kulke, MD, MMSc of Dana-Farber and Harvard Medical School explains whether or not somatostatin analogues were needed to see efficacy in treatment for carcinoid syndromes. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, E...
by:NCCN2017 | 694 views
00:56
Matthew H. Kulke, MD, MMSc of Dana-Farber and Harvard Medical School gives an overview of his discussion, Novel Treatment Options for Neuroendocrine Tumors, which was presented at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Effic...
by:NCCN2017 | 692 views
00:49
Matthew H. Kulke, MD, MMSc of Dana-Farber and Harvard Medical School discusses the results of the NETTER-1 study, which concluded with patients who were treated with octreotide had significantly improved progression free survival compared to patients who were not treated with the drug. This was reco...
by:NCCN2017 | 2363 views
01:49
Kilian E. Salerno, MD of Roswell Park Cancer Institute explains what to do with patients who have neo-adjuvant chemotherapy and how the response to chemotherapy affects the radiation oncologist's decision on what should be treated or not. She states that based on the guidelines, the role of radiati...
by:NCCN2017 | 354 views

About NCCN2017


Links
Channel Url: